MARKET

TBPH

TBPH

Theravance Bioph
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.62
-0.52
-5.69%
After Hours: 8.62 0 0.00% 16:19 05/18 EDT
OPEN
8.94
PREV CLOSE
9.14
HIGH
8.98
LOW
8.61
VOLUME
428.28K
TURNOVER
208.92K
52 WEEK HIGH
18.83
52 WEEK LOW
6.10
MARKET CAP
656.11M
P/E (TTM)
-4.1934
1D
5D
1M
3M
1Y
5Y
Theravance Biopharma, Inc. (NASDAQ:TBPH) About To Shift From Loss To Profit
We feel now is a pretty good time to analyse Theravance Biopharma, Inc.'s ( NASDAQ:TBPH ) business as it appears the...
Simply Wall St. · 5d ago
Theravance's (TBPH) Q1 Earnings and Sales Miss Estimates
Theravance (TBPH) reports wider-than-expected loss for the first quarter of 2022. Revenues decline year over year.
Zacks · 05/06 20:15
Theravance Biopharma (TBPH) Reports Q1 Loss, Lags Revenue Estimates
Theravance Bio (TBPH) delivered earnings and revenue surprises of -100% and 20.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/05 23:15
BRIEF-Theravance Biopharma, Inc. Reports First Quarter 2022 Financial Results
reuters.com · 05/05 22:56
Theravance Biopharma Q1 EPS $(0.34) Misses $(0.11) Estimate, Sales $13.20M Miss $14.48M Estimate
Theravance Biopharma (NASDAQ:TBPH) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.11) by 209.09 percent. This is a 72.58 percent increase over losses of $(1.24) per
Benzinga · 05/05 21:41
Theravance Biopharma GAAP EPS of -$0.34 misses by $0.23, revenue of $13.2M misses by $1.28M
Theravance Biopharma press release (NASDAQ:TBPH): Q1 GAAP EPS of -$0.34 misses by $0.23. Revenue of $13.2M (-7.4% Y/Y) misses by $1.28M.
Seekingalpha · 05/05 20:34
-- Earnings Flash (TBPH) THERAVANCE BIOPHARMA Posts Q1 Revenue $13.2M, vs. Street Est of $14.5M
MT Newswires · 05/05 16:24
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 05/05 12:43
More
No Data
Learn about the latest financial forecast of TBPH. Analyze the recent business situations of Theravance Bioph through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
28.57%Buy
42.86%Hold
28.57%Under-perform
0.00%Sell
Analyst Price Target
The average TBPH stock price target is 10.33 with a high estimate of 14.00 and a low estimate of 8.00.
High14.00
Average10.33
Low8.00
Current 8.62
EPS
Actual
Estimate
-0.76-0.51-0.27-0.02
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 166
Institutional Holdings: 78.37M
% Owned: 102.97%
Shares Outstanding: 76.12M
TypeInstitutionsShares
Increased
47
6.08M
New
21
3.05M
Decreased
28
8.79M
Sold Out
23
1.85M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-1.80%
Pharmaceuticals & Medical Research
-2.06%
Key Executives
Chairman/Chief Executive Officer/Director
Rick Winningham
Chief Financial Officer/Senior Vice President
Andrew Hindman
Senior Vice President
Rhonda Farnum
Senior Vice President
Richard Graham
Lead Director/Independent Director
William Young
Independent Director
Laurie Alsup
Independent Director
Eran Broshy
Independent Director
Burton Malkiel
Independent Director
Dean Mitchell
Independent Director
Donal O'Connor
Independent Director
Deepika Pakianathan
No Data
No Data
About TBPH
Theravance Biopharma, Inc. is a diversified biopharmaceutical company, which is primarily focused on the discovery, development and commercialization of organ-selective medicines. The Company develops transformational medicines to improve the lives of patients suffering from serious illnesses. The Company's research is focused in the areas of inflammation and immunology. It applies organ-selective knowledge to biologically compelling targets to discover and develop medicines, which are designed to treat underserved localized diseases and to limit systemic exposure. The Company is developing lung-selective medicines to treat respiratory disease, including YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its revefenacin is a long-acting muscarinic antagonist (LAMA). Its programs also include Nezulcitinib, Ampreloxetine (TD-9855), Izencitinib, TD-5202 and TD-8236.

Webull offers kinds of Theravance Biopharma Inc stock information, including NASDAQ:TBPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TBPH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TBPH stock methods without spending real money on the virtual paper trading platform.